Edwards Lifesciences (EW) Reports In-Line Q4 EPS, Q1 EPS Guidance Comes in Light

Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $1.17, in-line with the analyst estimate of $1.17. Revenue for the quarter came in at $978 million versus the consensus estimate of $975.92 million.

GUIDANCE:

Edwards Lifesciences sees Q1 2019 EPS of $1.15-$1.25, versus the consensus of $1.30. Edwards Lifesciences sees Q1 2019 revenue of $950-1.01 million, versus the consensus of $997.57 million.

Edwards Lifesciences sees FY2019 EPS of $5.05-$5.30, versus the consensus of $5.21.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Lumentum shares rise on analyst upgrades, AI demand outlook
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'